Authors
Paul Gerard Richardson, Michel Delforge, Meral Beksaç, Patrick Wen, JL Jongen, O Sezer, Evangelos Terpos, Nikhil Munshi, Antonio Palumbo, SV Rajkumar, Jean-Luc Harousseau, P Moreau, H Avet-Loiseau, JH Lee, Michele Cavo, Giampaolo Merlini, Peter Voorhees, WJ Chng, A Mazumder, Shariq Usmani, Hermann Einsele, R Comenzo, Robert Orlowski, David Vesole, JJ Lahuerta, R Niesvizky, David Siegel, MV Mateos, Meletios Dimopoulos, Sagar Lonial, Sundar Jagannath, Joan Bladé, J San Miguel, Gareth Morgan, KC Anderson, BGM Durie, Pieter Sonneveld
Publication date
2012/4
Source
Leukemia
Volume
26
Issue
4
Pages
595-608
Publisher
Nature Publishing Group
Description
Peripheral neuropathy (PN) is one of the most important complications of multiple myeloma (MM) treatment. PN can be caused by MM itself, either by the effects of the monoclonal protein or in the form of radiculopathy from direct compression, and particularly by certain therapies, including bortezomib, thalidomide, vinca alkaloids and cisplatin. Clinical evaluation has shown that up to 20% of MM patients have PN at diagnosis and as many as 75% may experience treatment-emergent PN during therapy. The incidence, symptoms, reversibility, predisposing factors and etiology of treatment-emergent PN vary among MM therapies, with PN incidence also affected by the dose, schedule and combinations of potentially neurotoxic agents. Effective management of treatment-emergent PN is critical to minimize the incidence and severity of this complication, while maintaining therapeutic efficacy. Herein, the state of …
Total citations
Scholar articles
PG Richardson, M Delforge, M Beksaç, P Wen… - Leukemia, 2012